Die medikamentöse Behandlung motorischer Komplikationen im Spätstadium des Morbus Parkinson

Zusammenfassung

Die Mehrzahl aller Parkinson-Patienten entwickelt im Laufe der medikamentösen Therapie ihrer Erkrankung motorische Probleme wie zunehmend schlechteres Ansprechen auf dopaminerge Medikation, Fluktuationen und Dyskinesien. Zudem treten häufig nichtmotorische Probleme wie Demenz, Angst, Depression, autonome Störungen und therapieresistente Phänomene wie Gangstörungen, Sprechstörungen, Fallneigung und Freezing hinzu. Die Behandlung dieser Komplikationen stellt eine Herausforderung sowohl für den Arzt als auch für den Patienten und seine Angehörigen dar. In diesem Artikel werden medikamentöse Therapiestrategien zur Behandlung von Komplikationen im Spätstadium des M. Parkinson zusammengefasst.

Abstract

The majority of patients with Parkinson's disease experiences motor complications during long-term treatment of their disease including a decreasing response to dopaminergic stimulation, motor fluctuations, and dyskinesias. Many patients also develop non-motor problems such as dementia, depression, autonomic dysfunction and therapy-resistent phenomena like gait disorders, speech disorders, postural instability, falls, and freezing. This article summarizes current treatment strategies in the drug management of motor complications in advanced Parkinson's disease.

Literatur

• 1 Cedarbaum J M, Gandy S E, McDowell F H. Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.  Neurology. 2000;  41 622-629
• 2 Kumar A, Huang Z, Fuente-Fernandez R. Mechanisms of motor complications in treatment of Parkinson's disease.  Adv Neurol. 2003;  91 193-199
• 3 Olanow C W, Fahn S, Muenter M. et al . A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.  Mov Disord. 1994;  9 40-47
• 4 Inzelberg R, Nisipeaunu P, Rabey J M. et al . Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.  Neurology. 1996;  47 785-788
• 5 Cristina S, Zangaglia R, Mancini F. et al . High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.  Clin Neuropharmacol. 2003;  26 146-150
• 6 Gimenez-Roldan S, Esteban E M, Mateo D. Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios.  Clin Neuropharmacol. 2001;  24 346-351
• 7 Rinne U K, Larsen J P, Siden A. et al . Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations.  Neurology. 1998;  51 1309-1314
• 8 Goetz C. Treatment of advanced Parkinson's disease: an evidence-based analysis.  Adv Neurol. 2003;  91 213-228
• 9 Rascol O, Payoux P, Ory F. et al . Limitations in current Parkinson's disease therapy.  Ann Neurol. 2003;  53, Suppl 3 S3-S15
• 10 Liebermann A, Olanow C W, Sethi K. and the Ropinirol Study Group . A multicenter trial of ropinirol as adjunct treatment for Parkinson's disease.  Neurology. 1998;  51 1057-1062
• 11 Guttman M. and the International Pramipexol-Bromocriptin Study Group . Double-blind, randomized, placebo-controlled study to compare safety, tolerance, and efficacy of pramipexol and bromocriptine in advanced Parkinson's disease.  Neurology. 1997;  49 1060-1065
• 12 Mungersdorf M, Sommer U, Sommer M, Reichmann H. High-dose therapy with ropinirole in patients with Parkinson's disease.  J Neural Transm. 2001;  108 1309-1317
• 13 Wolters E C, Tesselaar H JM. International Sinemet Study Group . International double-blind study of Sinemet CR and standard Sinemet in 170 patients with fluctuating Parkinson's disease.  J Neurol. 1996;  243 235-240
• 14 Verhagen-Metman L, Del Dotto P, Munckhof P van den. et al . Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.  Neurology. 1998;  50 1323-1326